Literature DB >> 16429425

Cystic fibrosis mutations with widely variable phenotype: the D1152H example.

H Mussaffi1, D Prais, M Mei-Zahav, H Blau.   

Abstract

D1152H is a type IV cystic fibrosis transmembrane regulator (CFTR) mutation associated with abnormal chloride gating. Although comprising 5-6% of mutations on genetic screening, clinical reports of cystic fibrosis (CF) are rare, suggesting that the disease is mild, atypical, or even absent. We describe our experience, which contrasts with this assumption, in a retrospective case series encompassing 91 CF patients (74 Jewish) aged 8 months to 56 years, from 2000-2005. Nine patients of varied Jewish ethnic origins were homozygous (2 patients) or compound heterozygous for D1152H with 11 of 182 potential alleles (6%). Five were diagnosed at age 33-49 years. Of 4 infants, 1 was diagnosed by prenatal screening, 1 had a prenatal dilated bowel, and 1 had pulmonary symptoms. Sweat chloride was 28-120 meq/l. Three adults had chronic mucoid Pseudomonas aeruginosa in sputum, and a forced expired volume in 1 sec (FEV1) of 20-55%. One was on bilevel positive airway pressure (BIPAP) ventilation. The infants had pulmonary symptoms that responded well to therapy. All 9 patients had good nutrition, 6 were pancreatic-sufficient, and 3 adults had subclinical pancreatic insufficiency. Three adults had recurrent pancreatitis. None had a bowel obstruction. Two of 3 adult males were fertile. Although asymptomatic at times, the D1152H mutation is associated with a broad clinical spectrum. This information is crucial for genetic counseling. Lung disease may be evident from infancy, and is severe in some adults, although all have outlived the median life expectancy of CF. Hopefully, with early diagnosis and therapy, prognosis can be good. A multicenter study of this mutation is warranted. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16429425     DOI: 10.1002/ppul.20343

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  7 in total

1.  A comparative study of five technologically diverse CFTR testing platforms.

Authors:  Monique A Johnson; Marvin J Yoshitomi; C Sue Richards
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

2.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

3.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

Authors:  Drucy Borowitz; Richard B Parad; Jack K Sharp; Kathryn A Sabadosa; Karen A Robinson; Michael J Rock; Philip M Farrell; Marci K Sontag; Margaret Rosenfeld; Stephanie D Davis; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

4.  Cystic fibrosis newborn screening: distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates.

Authors:  Valentina Paracchini; Manuela Seia; Sara Raimondi; Lucy Costantino; Patrizia Capasso; Luigi Porcaro; Carla Colombo; Domenico A Coviello; Tiziana Mariani; Emanuela Manzoni; Monica Sangiovanni; Carlo Corbetta
Journal:  JIMD Rep       Date:  2011-11-04

5.  Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.

Authors:  Claire L Keating; Xinhua Liu; Emily A Dimango
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

Review 6.  Atypical cystic fibrosis: identification in the primary care setting.

Authors:  Carrie A Schram
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

7.  Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis.

Authors:  Jessica LaRusch; Jinsei Jung; Ignacio J General; Michele D Lewis; Hyun Woo Park; Randall E Brand; Andres Gelrud; Michelle A Anderson; Peter A Banks; Darwin Conwell; Christopher Lawrence; Joseph Romagnuolo; John Baillie; Samer Alkaade; Gregory Cote; Timothy B Gardner; Stephen T Amann; Adam Slivka; Bimaljit Sandhu; Amy Aloe; Michelle L Kienholz; Dhiraj Yadav; M Michael Barmada; Ivet Bahar; Min Goo Lee; David C Whitcomb
Journal:  PLoS Genet       Date:  2014-07-17       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.